Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
Dual c-Jun N-terminal kinase-cyclin D1 and extracellular signal-related kinase-c-Jun disjunction in human melanoma
1]heptan-2-yl)prop-2-en-1-one
SCR7: a NHEJ inhibitor promotes the efficiency of HDR 4–5-fold for CRISPR editing in both human and mouse cell lines
AR7 was shown to protect cells from oxidative stress and proteotoxicity
It increases H3K4 methylation selectively at genomic regions bound by LSD1
Canertinib HCl - CAS# 289499-45-2 60273 Dual c-Jun N-terminal kinase-cyclin D1Canertinib, also known as CI1033 and PD183805, CAS No. 289499 45 2, is a potent ErbB inhibitor for the treatment of cancer. It is an irreversible tyrosine kinase inhibitor with activity against EGFR (IC50 0. 8 nM), HER 2 (IC50 19 nM) and ErbB 4 (IC50 7 nM). By 2015, Pfizer had discontinued development of the drug. Canertinib has been reported as a substrate for OATP1B3. Interaction of canertinib with OATP1B3 may alter its hepatic disposition and can